

Motif Bio PLC

07:45 24 Jun 2019

Motif Bio presents new iclaprim data at industry conference in California

Motif Bio PLC (LON:MTFB) has released new data for its iclaprim antibiotic at a major industry conference in San Francisco, California.

The AIM- and Nasdaq-listed biopharma presented three posters at the American Society for Microbiology (ASM) Microbe 2019 meeting over the weekend.

READ: US drugs regulator encourages Motif to carry further icalprim study
The first presentation focused on dosage, with data showing that the 80mg fixed doses given to patients in the most recent REVIVE phase III trial were more efficacious than the weight-based doses given in earlier studies.

"The fixed dose regimen may help reduce the resources required in hospitals, since dosage adjustment by clinicians is avoided, and overall treatment costs may be lower, especially in patients with obesity or renal impairment," said Motif.

A second poster highlighted the diverse patient population in the REVIVE and earlier ASSIST phase III studies.

In total, 1,093 patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) were treated with iclaprim in the studies, with older patients and those with co-morbidities such as obesity, diabetes and renal impairment were "well-represented".

In the REVIVE and ASSIST trials, respectively: 12% and 16% of patients treated with iclaprim were 65 or older; 15% and 8% were obese; 9% and 12% had diabetes; and 15% and 41% had renal impairment.

Antibiotic resistance a major global issue

In the third poster, Motif showed off iclaprim's "potent activity" against various Gram-positive multi-drug resistant streptococci - the bacteria that can cause disorders such as pneumonia.

Streptococci is known for its resistance to azithromycin, clindamycin and tetracycline - three of the most common antibiotics currently used to fight bacterial infections.

"Given the growing public health concern about antibiotic resistance, it is important to continue to monitor the activity of iclaprim against these bacteria," Motif added.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Price: 0.15

Market Cap: £728.02 k

1 Year Share Price Graph



January 2019 July 2019 January 2020

Share Information

Code: MTFB

Listing: AIM

52 week **High** **Low**
44.9 0.1068

Sector: Pharma & Biotech

Website: www.motifbio.com

Company Synopsis:

Motif Bio is a clinical-stage biopharmaceutical company focused on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant Gram-positive bacteria, including MRSA.

action@proactiveinvestors.com

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).